HVC
Healthcare Value Capital Portfolio holdings
AUM
$38.5M
This Quarter Return
+8.74%
1 Year Return
+22.29%
3 Year Return
+31.09%
5 Year Return
+125.72%
10 Year Return
–
AUM
$39.2M
AUM Growth
+$39.2M
(+51%)
Cap. Flow
+$313K
Cap. Flow
% of AUM
0.8%
Top 10 Holdings %
Top 10 Hldgs %
75.13%
Holding
27
New
9
Increased
2
Reduced
2
Closed
4
Top Buys
| 1 |
Pfizer
PFE
|
$3.62M |
| 2 |
Collegium Pharmaceutical
COLL
|
$2.37M |
| 3 |
Ironwood Pharmaceuticals
IRWD
|
$2.24M |
| 4 |
AMYT
Amryt Pharma plc American Depositary Shares
AMYT
|
$2.17M |
| 5 |
Alkermes
ALKS
|
$1.87M |
Top Sells
| 1 |
VYNE Therapeutics
VYNE
|
$11M |
| 2 |
AbbVie
ABBV
|
$3.75M |
| 3 |
McKesson
MCK
|
$1.74M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
$1.65M |
| 5 |
Cardinal Health
CAH
|
$1.34M |
Sector Composition
| 1 | Healthcare | 95.39% |
| 2 | Consumer Staples | 3.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Gilead Sciences
GILD
$140B
| $4.85M | 10.8% | 75,000 +25,000 | +50% | +$1.62M |
|
|
2
Pfizer
PFE
$141B
| $3.62M | 8.07% | +100,000 | New | +$3.62M |
|
3
GSK
GSK
$79.9B
| $3.57M | 7.95% | 100,000 | – | – |
|
|
CLVS
4
DELISTED
Clovis Oncology, Inc.
CLVS
| $3.16M | 7.04% | 450,000 +200,000 | +80% | +$1.4M |
|
|
5
VYNE Therapeutics
VYNE
$8.16M
| $2.74M | 6.1% | 400,000 -1,600,000 | -80% | -$11M |
|
|
TYME
6
DELISTED
Tyme Technologies, Inc. Common Stock
TYME
| $2.67M | 5.95% | 1,500,000 -675,000 | -31% | -$1.2M |
|
|
7
Collegium Pharmaceutical
COLL
$1.22B
| $2.37M | 5.28% | +100,000 | New | +$2.37M |
|
|
8
Ironwood Pharmaceuticals
IRWD
$214M
| $2.24M | 4.98% | +200,000 | New | +$2.24M |
|
|
AMYT
9
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
| $2.17M | 4.83% | +155,555 | New | +$2.17M |
|
|
ATRS
10
DELISTED
Antares Pharma, Inc.
ATRS
| $2.06M | 4.58% | 500,000 | – | – |
|
|
11
Alkermes
ALKS
$4.78B
| $1.87M | 4.16% | +100,000 | New | +$1.87M |
|
12
Bristol-Myers Squibb
BMY
$96B
| $1.58M | 3.51% | +25,000 | New | +$1.58M |
|
13
Merck
MRK
$210B
| $1.54M | 3.43% | +20,000 | New | +$1.54M |
|
14
Greenlane Holdings
GNLN
$4.71M
| $1.33M | 2.95% | 250,000 | – | – |
|
15
Aurinia Pharmaceuticals
AUPH
$1.58B
| $1.3M | 2.89% | +100,000 | New | +$1.3M |
|
16
AstraZeneca
AZN
$248B
| $1.24M | 2.77% | +25,000 | New | +$1.24M |
|
|
ADMS
17
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $480K | 1.07% | 100,000 | – | – |
|
|
GMDA
18
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
| $405K | 0.9% | 50,000 | – | – |
|
|
19
AbbVie
ABBV
$372B
| – | – | -35,000 | Closed | -$3.75M |
|
|
AMRN
20
Amarin Corp
AMRN
$311M
| – | – | 0 | – | – |
|
|
21
Cardinal Health
CAH
$35.5B
| – | – | -25,000 | Closed | -$1.34M |
|
|
22
Jazz Pharmaceuticals
JAZZ
$7.75B
| – | – | -10,000 | Closed | -$1.65M |
|
|
23
McKesson
MCK
$85.4B
| – | – | -10,000 | Closed | -$1.74M |
|
24
Moderna
MRNA
$9.37B
| – | – | 0 | – | – |
|
25
Novavax
NVAX
$1.21B
| – | – | 0 | – | – |
|